XML 51 R44.htm IDEA: XBRL DOCUMENT
v3.25.2

Consolidated Variable Interest Entity - Fortis - Additional Information (Detail) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended |
--- | --- | --- | ---
May 31, 2023 | Mar. 31, 2024 | Jun. 30, 2025
Third Party Shareholders [Member] | Nonredeemable NCI [Member] |  |  |
Business Acquisition [Line Items] |  |  |
Ownership percentage | 100.00% |  | 100.00%
Other Investors [Member] | Nonredeemable NCI [Member] |  |  |
Business Acquisition [Line Items] |  |  |
Ownership percentage | 98.00% |  | 98.00%
Series A Preferred Shares [Member] | Nonredeemable NCI [Member] |  |  |
Business Acquisition [Line Items] |  |  |
Ownership percentage | 2.00% |  | 2.00%
Fortis Therapeutics [Member] |  |  |
Business Acquisition [Line Items] |  |  |
Payment to options exercised | $ 80.0 |  |
Contingent payment associated with business acquisition | 200.0 |  |
Product development obligations | $ 5.4 | $ 1.7 |

X
- Definition Payment to options exercised + References No definition available. + Details
Name: | fgen_PaymentToOptionsExercised
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Product Development Costs + References No definition available. + Details
Name: | fgen_ProductDevelopmentCosts
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5 + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (d) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_OwnershipAxis=fgen_ThirdPartyShareholdersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=us-gaap_OtherInvesteesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=fgen_OtherInvestorsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=fgen_FortisTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |